Fig. 6.

Combination therapy with Fc-optimized anti-CD40 agonist antibody 2141-V11 and IL-15 enhances antitumor memory responses. (A) Schematic of subcutaneous rechallenge (10-fold tumor cell dose) of humanized hCD40/hFcγR mice surviving long-term (>90 d after initial orthotopic MB49 bladder tumor implantation) following initial therapy with anti-CD40 antibody 2141-V11 with or without IL-15. (B) Tumor growth (in the absence of any additional therapy) of long-term survivors compared with naïve mice receiving an equivalent MB49 tumor cell implant (n = 2 to 5 mice per group; bars represent SD). (C) Representative flow cytometry plots and quantification across mice (n = 2 to 5 mice per group) of CD44^hiCD122⁺ CD8 T cells (Top), CD44^hiCD122⁺CD62L⁺ CD8 T cells (Middle), and CD11b⁺KLRG1⁺CD27⁻ NK cells (Bottom) in the peripheral blood of mice surviving long-term (day 110) after primary tumor implantation and tumor rechallenge. *P < 0.05, **P < 0.01, and ****P < 0.0001.